Press for Qumas
QUMAS today announced that Samsung Bioepis has selected QUMAS ComplianceSP on Microsoft SharePoint 2010 to manage all of its regulatory documents following an extensive vendor evaluation process. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen Idec to develop, manufacture, and market biosimilars. Both Samsung Biologics and Biogen Idec are existing QUMAS customers, and are displaying their commitment to and satisfaction with QUMAS in their selection of ComplianceSP for their new joint venture.
Samsung Bioepis is building a state-of-the-art research and development center in Song-do Incheon, Korea. It is expected that the center will be completed by the end of the year.
QUMAS, the global leader in regulatory compliance solutions, today announced the opening of a new Asian office in Singapore. This office will serve as a base for QUMAS Sales and Marketing in Asia, as well as provide a central hub for QUMAS Professional Services and Partners in the region.